Regarding their activity the literature is scanty. Further studies are needed to understand their complex and heterogeneous effects. Chimeric somatostatin-dopamine compounds (dopastatins) with high affinity for SSTRs 2 and D2 receptor (D2R) (BIM-23A387) or to SSTRs 2, 5 and D2R LDN-193189 in vivo (BIM-23A760) have been showed to inhibit cell proliferation of the non-small-cell lung cancer cell line Calu-6, which expresses SSTRs 2, 5 and D2R with higher potency and efficacy than SSTR 2 and D2R analogues [99]. BIM23A760 can also inhibit ECL cell proliferation with similar potency but with higher efficacy than lanreotide and

D2R analogue [9]. The enhanced potency/efficacy of BIM-23A387 and Torin 2 BIM-23A760 may in part be due to the high affinity of these compounds for SSTR 2. However, SSTR 2 can heterodimerize with SSTR 5, and SSTRs 2 and 5 can form heterodimers with D2R which can alter receptor ligand binding affinity and/or signaling and/or receptor trafficking [100–102]. The presence of SSTRs in a higher density in NETs and their ability to form a receptor-ligand complex, can permit the internalisation and the accumulation of radiopharmaceutical inside the tumour [103]. A novel targeted cytotoxic somatostatin octapeptide conjugates such as RC-121 and RC-160 coupled to doxorubicin or its

superactive derivative, 2-pyrrolino-DOX (AN-201) was synthesised from Schally and coworkers [56]. AN-238, which contains AN-201 linked to carrier RC-121, has been demonstrated to suppress the growth of Hs746T and NCI-N87 human gastric cancers, which display a high concentration of SSTRs 2 and 5 and seems to target vascular SSTRs in a xenograft tumour model derived from SSTRs negative tumour cells [56]. Another Etofibrate cytotoxic somatostatin analog termed JF-10-81 has been synthesized by Coy and coworkers. This somatostatin analogue, conjugated to camptothecin, inhibits prostate cancer PC-3 cell invasion through a signaling pathway involving PI3K, integrin αVβ3/αVβ5 and matrix metalloproteinases 2 and 9 and exhibited anti-invasive and anti-angiogenic properties in

vivo [103]. SSTRs are able to form a receptor-ligand complex, that permit the internalisation and the accumulation of the radiopharmaceutical inside the tumour. Peptide-receptor radionuclide therapy (PRRT) represents an important treatment strategy for tumours that express adequate densities of SSTRs and has proven to be safe and effective. It was initially performed using indium-111 [19, 104]. Recently, the development of somatostatin peptides with higher receptor affinity conjugated with radio-metal TPX-0005 concentration labelling chelators, such as DOTA (1,4,7,10-tetrazacyclo-dodecane-N, N’, N”", N”"‘-tetraacetic acid), which may be allow stable labelling with gallium, yttrium or lutetium, changing the affinity profile for particular subtypes of SSTRs can permit new therapeutic options [105].